Abstract
We enrolled nine consecutive patients affected by newly diagnosed
polymyalgia rheumatica and decompensated diabetes mellitus. All patients
were treated with etanercept (25 mg twice weekly) and prednisone and
were followed up to 1 year. At the sixth-month follow-up, etanercept and
prednisone were withdrawn. Patients were seen at regular intervals (days
0, 30, 60, 90, 150, 180) and the following variables determined:
erythrocytes sedimentation rate, C-reactive protein, fasting serum
glucose, pain measured by visual analog scale, and the Health Assessment
Questionnaire. Our results indicate that etanercept might have some
steroid-sparing effects, but controlled investigations are needed to
support etanercept use in clinical practice for this kind of patients.
Lingua originale | English |
---|---|
pagine (da-a) | 89-92 |
Numero di pagine | 4 |
Rivista | Clinical Rheumatology |
Volume | 28 |
Stato di pubblicazione | Published - 2009 |
All Science Journal Classification (ASJC) codes
- ???subjectarea.asjc.2700.2745???